SCHEMBL25003833

SCHEMBL25003833

C=N/C=C\C=C(/C)NC(=O)Oc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
MAPT P10636 3/20 0.42
CYP1A2 P05177 1/20 0.42
RAD51 Q06609 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
THRB P10828 1/20 0.37
GFER P55789 1/20 0.37
GAA P10253 3/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 2/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23432002 0.80 HSD17B10 (0.42) ALDH1A1MAPTCYP1A2RAD51GAA
SCHEMBL22648030 0.72 ALDH1A1 (0.54) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL13019613 0.71 ALDH1A1 (0.62) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL20609439 0.71 MAPT (0.46) ALDH1A1MAPTCYP1A2MEN1KMT2A
SCHEMBL2551644 0.71 ALDH1A1 (0.55) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL21086605 0.70 ALDH1A1 (0.47) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL9425068 0.69 ALDH1A1 (0.56) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL5279705 0.68 ALDH1A1 (0.52) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL3074679 0.68 ALDH1A1 (0.52) ALDH1A1MAPTCYP1A2RAD51MEN1
SCHEMBL9424978 0.67 TGM2 (0.51) ALDH1A1MAPTCYP1A2RAD51MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045421-A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, AHCY ALDH1A1 2620/4885MAPT 4056/4885CYP1A2 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.